Food Intake and IgA Microbiota in Anorexia Nervosa (AAMIAM)

Centre Hospitalier Universitaire de Saint Etienne

Status: Terminated

Conditions: Healthy Volunteer; Anorexia Nervosa

Treatments: Other: Food intake evaluation; Other: Stool sample

Study type: Interventional

Funder types: Other

Identifiers

NCT05842343

2023-A00318-37 (Other Identifier)

22CH356

Details and patient eligibility

About

Anorexia nervosa is characterized by intestinal dysbiosis, related to the feeding behavior impairment presented by these patients. Pathophysiologic hypotheses are involving the trouble of the microbiota-gut-brain axis in the field of mental diseases.

Full description

Anorexia nervosa is characterized by intestinal dysbiosis, related to the feeding behavior impairment presented by these patients. Here we aim to characterize the IgA-coated fraction of bacteria from the intestinal microbiota, linked to the regulation of the mucosal immune system and the epithelium physiology. Abnormalities of this microbiota are reported in inflammatory bowel disease and are associated to immune trouble. As food intake plays a key role in shaping microbiota, we aim to correlate data from IgA microbiota to food intake specificity, and to anorexia nervosa phenotypes.

Enrollment: 14 patients

Sex: Female

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• female subject, adult, affiliated to a social security system, under the care of the eating disorder department of university hospital of st Etienne
• presenting a diagnosis of pure restrictive anorexia nervosa.

For acute subgroup : BMI between 11 and 17.5 kg/m2, patient with a first episode of restrictive anorexia nervosa or with hyperphagic episodes.

For the chronic subgroup: BMI between 11 and 17.5 kg/m2, disease evolving for more than 5 years.

For Healthy volunteer: BMI between 20 and 24 kg/m², stable weight for the last 3 months, no eating disorder or history of eating disorder

Exclusion criteria

• patient does not understand French.
• laxative treatment in progress or stopped for less than 15 days,
• antibiotic treatment in the two months preceding inclusion,
• pre-pro or symbiotic treatment in progress or in the month preceding inclusion,
• patient with one of the following comorbid disorders: celiac disease, chronic inflammatory bowel disease, lactose intolerance, unstabilized hyperthyroidism, unstabilized diabetes,
• subject under legal protective measures.

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

14 participants in 3 patient groups, including a placebo group

Acute anorexia nervosa

Experimental group

Description:

patient diagnose for a first episode of pure restrictive anorexia nervosa will be included. They will have stool sample and Food intake evaluation.

Treatment:

Other: Stool sample

Other: Food intake evaluation

Chronic anorexia nervosa

Experimental group

Description:

Patient diagnose for anorexia nervosa at least 5 years ago and still maintaining a significant thinness will be included. They will have stool sample and Food intake evaluation.

Treatment:

Other: Stool sample

Other: Food intake evaluation

Healthy control

Placebo Comparator group

Description:

Healthy Patient will be included. They will have stool sample and Food intake evaluation.

Treatment:

Other: Stool sample

Other: Food intake evaluation